Huiping Li

机构：Roche (Switzerland), Inner Mongolia Agricultural University, Hunan Normal University, Peking University, Inner Mongolia University, Northwest University, Peking University Cancer Hospital, People 's Hospital of Jilin Province, Shanghai Pulmonary Hospital, Southern Medical University Shenzhen Hospital, Hunan Provincial People's Hospital, Ministry of Education, Shenzhen Second People's Hospital, Inner Mongolia Medical University · ORCID：0000-0002-3331-647X

发表论文 432 篇 · 总被引 6739 次 · h-index 40

代表论文

• Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer (2025 · New England Journal of Medicine · 被引 46)
• Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2− breast cancer: The LINUXtrial (2025 · Cancer Cell · 被引 4)
• Marginal abatement costs of direct carbon emissions from municipal wastewater treatment plants: Insights for prioritizing pollution removal or carbon mitigation in collaborative control strategies (2025 · Resources Conservation and Recycling · 被引 3)
• Long-term survival outcomes and subtype variations between primary breast cancer and liver metastases in 542 patients with advanced breast cancer: insights from a real-world analysis (2025 · Discover Oncology · 被引 3)
• Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial (2025 · Signal Transduction and Targeted Therapy · 被引 2)
• Real-world outcomes of first-line treatment with HLX02 versus reference trastuzumab plus pertuzumab in HER2-positive metastatic breast cancer (2025 · The Oncologist · 被引 2)